Stocktoria
PALVELLA THERAPEUTICS, INC. PVLA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-12-18
PALVELLA THERAPEUTICS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $42.8M | $25.9M | $31.4M |
| R&D expense | $22.8M | $8.2M | $8.8M | $53.0M | $66.7M |
| Operating income | -$38.6M | -$14.1M | -$11.9M | -$43.5M | -$51.8M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$41.7M | -$17.4M | $18.7M | -$33.3M | -$45.7M |
| EPS (diluted) | $-3.71 | $-7.83 | $2.17 | — | $-0.71 |
| Operating cash flow | -$25.0M | -$10.8M | -$13.7M | -$59.9M | -$7.7M |
| Free cash flow | — | — | -$13.9M | -$61.0M | -$8.6M |
| Cash & equivalents | $58.0M | $83.6M | $7.3M | $38.6M | $117.8M |
| Total assets | $59.6M | $88.2M | $7.5M | $95.5M | $153.6M |
| Total liabilities | $31.6M | $25.6M | $11.4M | $67.6M | $102.8M |
| Shareholders' equity | $28.0M | $62.6M | -$74.5M | -$93.8M | $50.8M |
Source: SEC EDGAR filings · CIK 0001583648 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.